Nathan A. Pennell

64.7k total citations · 2 hit papers
175 papers, 5.4k citations indexed

About

Nathan A. Pennell is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Nathan A. Pennell has authored 175 papers receiving a total of 5.4k indexed citations (citations by other indexed papers that have themselves been cited), including 122 papers in Oncology, 115 papers in Pulmonary and Respiratory Medicine and 26 papers in Cancer Research. Recurrent topics in Nathan A. Pennell's work include Lung Cancer Treatments and Mutations (98 papers), Lung Cancer Research Studies (44 papers) and Lung Cancer Diagnosis and Treatment (43 papers). Nathan A. Pennell is often cited by papers focused on Lung Cancer Treatments and Mutations (98 papers), Lung Cancer Research Studies (44 papers) and Lung Cancer Diagnosis and Treatment (43 papers). Nathan A. Pennell collaborates with scholars based in United States, Italy and France. Nathan A. Pennell's co-authors include Wolfgang J. Streit, James Stevenson, Vamsidhar Velcheti, Susan C. Scott, Thomas J. Lynch, Sagar Rakshit, Monica Khunger, Vinay Pasupuleti, Adrían V. Hernández and Howard West and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Nathan A. Pennell

169 papers receiving 5.3k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Reactive microgliosis

1999 923 citations Nathan A. Pennell et al. profile →
Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer

2017 349 citations James Stevenson, Nathan A. Pennell et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nathan A. Pennell United States	34	2.7k	2.3k	1.2k	956	729	175	5.4k
Howard West United States	35	4.8k 1.7×	4.9k 2.1×	2.0k 1.7×	1.0k 1.1×	367 0.5×	190	8.6k
Tao Qin China	33	1.6k 0.6×	896 0.4×	1.3k 1.1×	970 1.0×	295 0.4×	128	3.9k
Yan Huang China	37	3.3k 1.2×	2.0k 0.8×	1.5k 1.2×	994 1.0×	118 0.2×	242	5.5k
Patrick Michl Germany	36	2.8k 1.0×	554 0.2×	2.3k 2.0×	1.3k 1.3×	492 0.7×	156	5.9k
Ronan J. Kelly United States	38	2.5k 0.9×	1.8k 0.8×	1.7k 1.4×	535 0.6×	182 0.2×	158	4.9k
Katherine B. Peters United States	35	1.1k 0.4×	1.1k 0.5×	1.3k 1.1×	803 0.8×	137 0.2×	230	4.6k
Athanassios P. Kyritsis United States	48	2.0k 0.7×	1.5k 0.7×	3.2k 2.7×	1.1k 1.1×	117 0.2×	173	7.9k
Amyn M. Rojiani United States	40	693 0.3×	739 0.3×	2.7k 2.2×	706 0.7×	1.3k 1.8×	139	5.9k
Jingqin Luo United States	42	3.2k 1.2×	1.4k 0.6×	2.6k 2.2×	2.1k 2.2×	197 0.3×	194	8.0k
Roberto Ferrara Italy	30	2.7k 1.0×	1.6k 0.7×	489 0.4×	390 0.4×	120 0.2×	144	4.5k

Countries citing papers authored by Nathan A. Pennell

Since Specialization

Citations

This map shows the geographic impact of Nathan A. Pennell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nathan A. Pennell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nathan A. Pennell more than expected).

Fields of papers citing papers by Nathan A. Pennell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nathan A. Pennell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nathan A. Pennell. The network helps show where Nathan A. Pennell may publish in the future.

Co-authorship network of co-authors of Nathan A. Pennell

This figure shows the co-authorship network connecting the top 25 collaborators of Nathan A. Pennell. A scholar is included among the top collaborators of Nathan A. Pennell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nathan A. Pennell. Nathan A. Pennell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pérol, M., Wei Li, Nathan A. Pennell, et al.. (2025). Taletrectinib in ROS1 + Non–Small Cell Lung Cancer: TRUST. Journal of Clinical Oncology. 43(16). 1920–1929. 10 indexed citations

Liu, Geoffrey, Yuichiro Ohe, Shunichi Sugawara, et al.. (2024). MA06.03 Efficacy and Safety of Taletrectinib in Patients with ROS1+ Non-Small Cell Lung Cancer: The Global TRUST-II Study. Journal of Thoracic Oncology. 19(10). S72–S73. 3 indexed citations

Khorrami, Mohammadhadi, et al.. (2024). 1222P Predicting pathological complete response to neoadjuvant chemoimmunotherapy in resected NSCLC with radiomic signatures. Annals of Oncology. 35. S785–S786.

Lee, Monica, Meera Patel, Hadil Zureigat, et al.. (2024). Survival outcomes of patients with extensive-stage small cell lung cancer who received treatment with atezolizumab in combination with carboplatin and etoposide: A propensity score adjusted cohort study.. Journal of Clinical Oncology. 42(16_suppl). 8096–8096. 1 indexed citations

Owonikoko, Taofeek K., Alberto Chiappori, Ryan D. Gentzler, et al.. (2024). Alisertib in patients with extensive-stage small-cell lung cancer: The phase 2 ALISCA-Lung1 study.. Journal of Clinical Oncology. 42(16_suppl). TPS8128–TPS8128. 1 indexed citations

Brose, Marcia S., C. Benedikt Westphalen, Kenneth L. Kehl, et al.. (2024). Outcomes of larotrectinib compared with real-world data from non-TRK inhibitor therapies in patients with TRK fusion cancer: VICTORIA study.. Journal of Clinical Oncology. 42(16_suppl). 3105–3105. 3 indexed citations

Pérol, M., Wei Li, Nathan A. Pennell, et al.. (2024). 1289P Pooled efficacy and safety from 2 pivotal phase II trials of taletrectinib in patients (Pts) with advanced or metastatic ROS1+ non-small cell lung cancer (NSCLC). Annals of Oncology. 35. S821–S821. 3 indexed citations

Delasos, Lukas, Mohammadhadi Khorrami, Vidya Sankar Viswanathan, et al.. (2024). Novel radiogenomics approach to predict and characterize pneumonitis in stage III NSCLC. npj Precision Oncology. 8(1). 290–290. 5 indexed citations

Qi, Peng, Gregory M.M. Videtic, Kevin L. Stephans, et al.. (2023). Clinical Nomogram Using Novel Computed Tomography–Based Radiomics Predicts Survival in Patients With Non–Small-Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy. JCO Clinical Cancer Informatics. 7(7). e2200173–e2200173. 3 indexed citations

10.

Zabor, Emily C., et al.. (2023). Clinical and financial implications of ADUARA trial on a real-world population.. Journal of Clinical Oncology. 41(16_suppl). 8526–8526.

11.

Pérol, M., Nong Yang, Yuichiro Ohe, et al.. (2023). 1373P Efficacy and safety of taletrectinib in patients (Pts) with ROS1+ non-small cell lung cancer (NSCLC): Interim analysis of global TRUST-II study. Annals of Oncology. 34. S788–S789. 9 indexed citations

12.

Braman, Nathaniel, Prateek Prasanna, Kaustav Bera, et al.. (2022). Novel Radiomic Measurements of Tumor-Associated Vasculature Morphology on Clinical Imaging as a Biomarker of Treatment Response in Multiple Cancers. Clinical Cancer Research. 28(20). 4410–4424. 19 indexed citations

13.

Freeman‐Daily, Janet, Michael Fisch, Emil Lou, et al.. (2022). The Rise of the Expert Patient in Cancer: From Backseat Passenger to Co-navigator. JCO Oncology Practice. 18(8). 578–583. 23 indexed citations

14.

Khorrami, Mohammadhadi, Kaustav Bera, Rajat Thawani, et al.. (2021). Distinguishing granulomas from adenocarcinomas by integrating stable and discriminating radiomic features on non-contrast computed tomography scans. European Journal of Cancer. 148. 146–158. 24 indexed citations

15.

Patil, Pradnya D., et al.. (2020). Cases from the Immune-Related Adverse Event Tumor Board: Diagnosis and Management of Immune Checkpoint Blockade-Induced Diabetes. The Oncologist. 25(11). 921–924. 6 indexed citations

16.

Pennell, Nathan A., Joel W. Neal, Jamie E. Chaft, et al.. (2018). SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 37(2). 97–104. 137 indexed citations

17.

Ahmad, Usman, Ali Hakim, Andrew Tang, et al.. (2018). Patterns of Recurrence and Overall Survival in Incidental Lung Cancer in Explanted Lungs. The Annals of Thoracic Surgery. 107(3). 891–896. 12 indexed citations

18.

Scott, Susan C. & Nathan A. Pennell. (2018). Early Use of Systemic Corticosteroids in Patients with Advanced NSCLC Treated with Nivolumab. Journal of Thoracic Oncology. 13(11). 1771–1775. 153 indexed citations

19.

Pennell, Nathan A.. (2012). Treating ALK-positive lung cancer in the weeks after the FDA approval of crizotinib.. PubMed. 18(5 Spec No. 2). SP84–7. 2 indexed citations

20.

Morgensztern, Daniel, Nathan A. Pennell, Janakiraman Subramanian, & Ramaswamy Govindan. (2011). Summary of Presentations from the 46th Annual Meeting of the American Society of Clinical Oncology (2010): Focus on Developmental Therapeutics Related to Lung Cancer. Clinical Lung Cancer. 12(2). 94–99. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact